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ABSTRACT
Despite recent progress in its treatment, Multiple Myeloma (MM) remains 
incurable and its associated bone disease persists even after complete remission. 
Thus, identification of new therapeutic agents that simultaneously suppress MM 
growth and protect bone is an unmet need. Herein, we examined the effects of 
Aplidin, a novel anti-cancer marine-derived compound, on MM and bone cells. In vitro, 
Aplidin potently inhibited MM cell growth and induced apoptosis, effects that were 
enhanced by dexamethasone (Dex) and bortezomib (Btz). Aplidin modestly reduced 
osteocyte/osteoblast viability and decreased osteoblast mineralization, effects that 
were enhanced by Dex and partially prevented by Btz. Further, Aplidin markedly 
decreased osteoclast precursor numbers and differentiation, and reduced mature 
osteoclast number and resorption activity. Moreover, Aplidin reduced Dex-induced 
osteoclast differentiation and further decreased osteoclast number when combined 
with Btz. Lastly, Aplidin alone, or suboptimal doses of Aplidin combined with Dex or 
Btz, decreased tumor growth and bone resorption in ex vivo bone organ cultures that 
reproduce the 3D-organization and the cellular diversity of the MM/bone marrow 
niche. These results demonstrate that Aplidin has potent anti-myeloma and anti-
resorptive properties, and enhances proteasome inhibitors blockade of MM growth 
and bone destruction. 
www.oncotarget.com                                  Oncotarget, 2019, Vol. 10, (No. 28), pp: 2709-2721
INTRODUCTION 
Multiple myeloma (MM) is the second most 
common hematologic malignancy and the most frequent 
cancer that involves bone [1, 2]. The bone/bone marrow 
(BM) niche plays a critical role in MM onset and 
progression. MM cells locate in specialized niches in the 
BM where they interact with stromal cells, endothelial 
cells, immune cells, osteoblasts, osteoclasts, adipocytes, 
and osteocytes [2, 3]. These interactions transform 
the bone/BM niche into an ideal environment for the 
proliferation and survival of MM cells. Further, actively 
expanding MM cells increase osteoclast numbers and 
activity, leading to development of lytic bone lesions that 
rarely heal due to a concomitant suppression of osteoblast 
bone forming activity [1, 4]. MM can cause pathologic 
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fractures and excruciating bone pain, which increase 
morbidity and mortality and diminish the quality of life 
of patients. Remarkable progress has been made in the 
treatment of MM in the past 10 years, however MM 
remains incurable in the majority of patients. In addition, 
osteolytic lesions persist in patients in remission with no 
evidence of marrow infiltration by MM cells [4, 5], thus 
prompting a continued search for additional therapeutic 
options that inhibit MM growth and protect bone health. 
Aplidin is a novel anti-cancer compound isolated 
from the marine tunicate Aplidium albicans [6–8]. In 
vitro studies showed that Aplidin has anti-MM activity 
against 19 MM cell lines including cells resistant 
to anti-MM agents frequently used in the clinic (i.e. 
melphalan, doxorubicin, thalidomide derivatives, and 
dexamethasone) and primary MM cells isolated from 
patients (13 out 16 showed response to Aplidin) [9]. 
Recently, Losada et al demonstrated that Aplidin targets 
the eukaryotic elongation factor 1A2 (EF1A2), which 
is overexpressed in MM cells [7]. Mechanistically, 
several pathways have been identified to mediate 
the effects of Aplidin on the viability of MM cells. 
Aplidin induces apoptosis in MM cells, which involves 
activation of p38 and c-jun NH(2)-terminal kinase 
signaling, Fas/CD95 translocation to lipid rafts, and 
ultimately caspase activation. In addition, Aplidin 
decreases the proliferation of MM cells, an effect 
mediated by the suppression of several proliferative 
genes. [9, 10]. In vivo, it has been reported that Aplidin 
has anti-MM activity in preclinical animal models [9, 
10]. Further, in a pivotal phase III trial of patients with 
relapsed or refractory MM, Aplidin in combination with 
dexamethasone (Dex) significantly reduced the risk 
of progression or death compared to Dex alone [11]. 
However, the effects of Aplidin, alone or in combination 
with anti-MM therapy, on bone cells and MM-induced 
bone disease are unknown. 
In this study, we examined the effects of Aplidin, 
alone or in combination with other anti-MM drugs, on 
MM cells and bone cells (osteocytes, osteoblasts, and 
osteoclasts). Using in vitro approaches and an ex vivo 
3D model of MM bone disease, we found that Aplidin 
decreased MM cell viability, and that this action was 
enhanced by the anti-MM drugs Dex and Bortezomib 
(Btz). In addition, Aplidin modestly decreased osteocyte 
and osteoblast viability, and this effect was exacerbated by 
Dex, but partially prevented by Btz. Importantly, Aplidin 
potently inhibited osteoclast precursor commitment 
and differentiation, inhibited mature osteoclast bone 
resorption, and reduced Dex-induced increases in 
osteoclast differentiation. These findings demonstrate that 
Aplidin inhibits both tumor growth and bone resorption, 
and suggest that Aplidin can enhance the clinical efficacy 
of proteasome inhibitors by potentiating their anti-tumor 
properties and reducing the risk of skeletal-related events 
by inhibiting resorption through acting on osteoclasts.
RESULTS 
The anti-myeloma effects of Aplidin are 
enhanced by dexamethasone and bortezomib
We first determined the dose- and time-dependent 
effects of Aplidin on the viability of murine and human 
MM cell lines. Concentrations higher than 1 nM of 
Aplidin decreased the viability of human JJN3 MM 
cells in a dose-dependent manner (EC50~10 nM) and 
progressively reduced MM cell viability from 24 h to 
48 h (Figure 1A and 1C). Aplidin also decreased the 
viability of murine 5TGM1 MM cells (Figure 1B). 
Aplidin induced MM cell death in a dose and time 
dependent manner in both JJN3 and 5TGM1 MM cells 
(Figure 1A and 1B), with an EC50 of ~10nM Aplidin for 
JJN3 MM cells and ~20 nM for 5TGM1 cells after 48 h 
of treatment (Figure 1C), and decreased the proliferation 
of JJN3 MM cells (Figure 1D). The elevated MM cell 
death induced by Aplidin was due to apoptosis, as 
treatment with the caspase 3 inhibitor DEVD fully 
prevented Aplidin-induced increases in MM cell death 
(Figure 1D). In contrast, DEVD did not affect the number 
of alive MM cells, which remained decreased by Aplidin 
(Figure 1D).
We next evaluated the effects of combinations of 
Aplidin with other anti-MM drugs on MM cell viability/
cell death. Treatment with Dex alone decreased the 
viability of JJN3 cells, increased MM cell death up to 
23%, and enhanced the effect of 10 nM Aplidin on MM 
cell death by 1.6-fold (39% vs 63% cell death, Aplidin vs 
Aplidin+Dex, respectively; Figure 1E). Btz also decreased 
JJN3 viability by 50%, augmented JJN3 cell death up to 
35%, and increased the number of JJN3 dead cells in 
combination with 10 nM Aplidin by 2.5-fold (20% vs 50% 
cell death, Aplidin vs Aplidin+Btz, respectively; Figure 
1F). These results demonstrate that Aplidin induces MM 
cell death and its anti-MM activity is further enhanced 
when combined with Dex and Btz.
Aplidin-mediated decrease in osteocyte viability 
is enhanced by dexamethasone and partially 
prevented by bortezomib
To gain insight into the effects of Aplidin in the 
skeleton, we first investigated its effects on osteocytes, 
the most abundant cells in bone. Aplidin 10nM increased 
the percentage of dead MLO-A5 osteocyte-like cells up 
to 10–15% after 48 h (Figure 2A), and inhibit MLO-A5 
osteocyte-like proliferation (Figure 2A, 2B). Mechanistic 
studies showed that Aplidin increases osteocyte cell death 
by inducing apoptosis. As shown in Figure 2B, treatment 
with the caspase 3 inhibitor DEVD fully blocked Aplidin-
induced increases in osteocyte cell death; however, 
treatment with DEVD did not prevent the decreased in the 
number of alive osteocytes induced by Aplidin. Further, 
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as shown previously [12], treatment with Dex increased 
osteocyte cell death to ~8%, and in combination with 
Aplidin 10 nM, Dex further increased Aplidin-induced 
osteocyte cell death by 1.8-fold (19% vs 37% cell death, 
Aplidin vs Aplidin+Dex, respectively; Figure 2C). 
In contrast, Btz did not alter osteocyte cell death and 
partially blunted the increase in dead osteocytes induced 
by Aplidin 10 nM (31% vs 19%, Aplidin vs Aplidin+Btz, 
respectively) (Figure 2D).
Co-administration of bortezomib partially 
prevents the decreases in osteoblast viability and 
function induced by Aplidin
We next examined the actions of Aplidin on 
osteoblasts. Concentrations of 1 nM Aplidin and higher 
increased cell death up to 10–20% after 48 h in OB-6 
osteoblastic cells (Figure 3A). As previously demonstrated, 
Dex increased osteoblast cell death, and when combined with 
Figure 1: The inhibition of MM cell viability by Aplidin is enhanced by Dex and Btz. (A–C) Human JJN3 and murine 
5TGM1 MM cells were treated with increasing concentrations of Aplidin and MM cell viability/death was evaluated after 24 h and 
48 h using MTT and Trypan blue uptake assays. JJN3 MM cells were treated with Aplidin 10 nM with/without DEVD (D), and increasing 
concentrations of Aplidin in the presence/absence of a fixed dose of Dex (E) or Btz (F) and cell viability/death was evaluated after 48 h. 
Representative experiments out of two are shown (n = 4–6 per condition). Bars represent means ± SD. *p < 0.05 vs vehicle; lines indicate 
p < 0.05 for Dex/Btz alone vs Dex/Btz + Aplidin.
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Aplidin 1 and 10 nM, it further enhanced this effect (10% vs 
15%, Aplidin 10 nM vs Aplidin 10 nM+Dex, respectively) 
(Figure 3B). As observed in osteocytes cultures, Btz did not 
alter the viability of osteoblasts; however, it partially reduced 
the increases in the number of dead osteoblasts induced 
by 10 nM Aplidin (8% vs 3%, Aplidin 10 nM vs Aplidin 
10 nM+Dex, respectively) (Figure 3C).
Continuous (5 days a week) and pulse (once a 
week) administration of 1–10 nM Aplidin decreased 
the matrix production and mineralization of OB-6 cells 
cultured under osteogenic conditions by 20% (Figure 3D 
and 3E). Further, consistent with the protective effects 
of Btz against Aplidin-induced osteoblast cell death, 
co-administration of Btz partially prevented (~50%) 
the reduction in mineralization induced by Aplidin 1 
nM (Figure 3E). Similar to the findings in OB-6 cells, 
continuous treatment with Aplidin 10 nM decreased 
matrix mineralization in pre-osteoblastic MC4 cells 
(Figure 3F). This effect was associated with decreases in 
the mRNA expression of Runx2, Collagen 1a, and alkaline 
phosphatase (Figure 3F).
Aplidin inhibits osteoclast precursor 
differentiation and the bone resorbing activity of 
mature osteoclasts
We also investigated the effects of Aplidin on 
osteoclast formation and mature osteoclasts. In vitro, 
osteoclast lineage cells exhibited higher sensitivity 
to Aplidin as compared to MM cells or cells of the 
osteoblastic lineage, as nM concentrations of Aplidin 
fully blocked the formation of CFU-GM colonies and 
osteoclast formation. Thus, the drug was tested at lower 
concentrations. 50 pM Aplidin decreased by 15% the 
number of CFU-GM colonies in cultures of murine bone 
marrow cells (Figure 4A). Moreover, concentrations 
as low as 0.01 pM of Aplidin reduced TRAP positive 
mononuclear osteoclast precursors by 10% (Figure 4B). In 
addition, Aplidin decreased the number of multinucleated 
osteoclasts by 40% (Figure 4C). Aplidin blunted the rapid 
(5–15 min) increase in ERK phosphorylation induced 
by RANKL, but did not affect RANKL-induced p38 
phosphorylation (Figure 4D), suggesting that Aplidin 
inhibited RANKL-induced differentiation of osteoclast 
precursors by preventing ERK activation. Treatment with 
Aplidin also decreased the RANKL-mediated induction of 
markers of osteoclast differentiation, including NFATc1, 
TRAP, and MMP-9 (Figure 4E). Further, treatment 
with Dex induced a 3.3-fold increase in the number of 
osteoclasts induced by RANKL, whereas Btz decreased the 
differentiation of osteoclast precursors by ~50% compared 
to vehicle-treated cells (Figure 4F). Addition of Aplidin to 
Dex treated marrow cultures resulted in a 25% reduction 
in the increase of TRAP+ multinucleated cells induced by 
Dex, and further decreased the number of osteoclasts in 
pre-osteoclast cultures treated with Btz (Figure 4F).
Figure 2: Aplidin decreases osteocyte viability. (A) Time (24–48 h) and dose-response (0–10 nM) to Aplidin in murine MLO-A5 
osteocyte-like cells. Evaluation of the effects of combinations of Aplidin with the caspase 3 inhibitor DEVD (B), Dex (C) and Btz (D) after 
48 h treatment. Representative experiments out of two are shown (n = 4–6 per condition). Bars represent means ± SD. *p < 0.05 vs vehicle; 
lines indicate p < 0.05 for Dex/Btz alone vs Dex/Btz + Aplidin, and Aplidin vs Aplidin + Btz.
Oncotarget2713www.oncotarget.com
We then tested the effects of Aplidin on mature bone 
resorbing osteoclasts. Aplidin decreased the number of 
mature osteoclasts in a dose-dependent manner, and 10 
pM Aplidin reduced the increase in Cathepsin K induced 
by RANKL in mature osteoclasts (Figure 5A). In addition, 
Aplidin, either alone and in combination with Dex and 
Figure 3: Aplidin decreases osteoblast viability and function and co-administration of Btz partially prevents these 
effects. (A–C) Cell viability and cell death was evaluated in murine OB-6 osteoblastic cells treated with Aplidin (0–10 nM) alone or in 
combination with Dex or Btz. Representative experiments out of two are shown (n = 4–6 per condition). Mineralization of OB-6 (D–E) 
and MC-4 (F) cells treated with/without Aplidin in the presence/absence of Btz for 14-21 days evaluated by Alizarin Red staining. Percent 
change was calculated over cells cultured with osteogenic media (OM) in the absence of Aplidin. Representative experiments out of two 
are shown (n = 3–4 per condition). Bars represent means ± SD. *p < 0.05 vehicle; lines indicate p values < 0.05 comparing Dex/Btz alone 
vs Dex/Btz + Aplidin, and Aplidin vs Aplidin + Btz.
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Btz, markedly decreased the number of resorption pits 
formed by mature osteoclasts plated on bovine bone slices. 
(Figure 5B and Supplementary Figure 1). 
Aplidin exhibits anti-myeloma and anti-
resorptive activities in an ex vivo 3D bone organ 
model of multiple myeloma
We next examined the effects of Aplidin on tumor 
growth and bone resorption using an ex vivo bone organ 
culture model of MM in which the three-dimensional 
organization and the cellular diversity of the MM/
bone marrow niche are preserved, thus providing a 
physiologically relevant environment (Figure 6A) 
[13–16]. After 3 days of culture, conditioned media 
(CM) collected from calvarial bones bearing MM cells 
exhibited a 19-fold increase in levels of the tumor marker 
IgG2b compared to CM derived from control bones. 
Three days of treatment with 10 nM Aplidin reduced 
the levels of IgG2b by 60% in CM from bones bearing 
MM cells (Figure 6B). After 12 days of treatment, 
Aplidin completely blocked tumor growth, as IgG2b 
levels in CM from bones bearing MM cells treated with 
Aplidin were indistinguishable from those found in 
CM from control bones (Supplementary Figure 2A). In 
this particular experiment, we were not able to detect 
significant increases in the levels of the bone resorption 
marker collagen type 1 cross-linked C-telopeptide (CTX) 
in CM from bones bearing MM. However, treatment with 
10 nM Aplidin for 3 days markedly decreased CTX to 
levels below those found in CM collected from control 
bones (Figure 6B). Further, CTX levels were undetectable 
Figure 4: Aplidin inhibits osteoclast precursor expansion and differentiation. (A) Evaluation of the effects of Aplidin (0–50 
pM) on proliferation and differentiation of hematopoietic progenitors (CFU-GM), (B) expansion of the osteoclast precursor population 
induced by M-CSF, and (C) RANKL-induced differentiation of osteoclast precursors. Representative images of osteoclast cultures are 
shown in panel C. (D) Analysis of protein levels of p-ERK, ERK, p-P38, and P38 in cell lysates collected from osteoclast precursors 
stimulated with RANKL (0–30 minutes). (E) Analysis of the protein levels of NFATc1, TRAP, and MMP9. (F) Number of TRAP+ 
osteoclasts after treatment with Aplidin in the presence/absence of Dex and Btz. Representative experiments out of two are shown (n = 
4 per condition). Bars represent means ± SD. *p < 0.05 vs vehicle; lines indicate p values < 0.05 comparing Dex/Btz alone vs Dex/Btz + 
Aplidin.
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in bones treated with 10nM Aplidin for 12 days 
(Supplementary Figure 2A). These findings are consistent 
with our in vitro studies showing decreased number of 
osteoclasts after Aplidin treatment, and support the 
notion that, in addition to its potent anti-MM properties, 
Aplidin also has the potential to block bone destruction by 
inhibiting bone resorption.
We next investigated in this model the effects of 
combinations of suboptimal doses of Aplidin, Dex, and 
Btz on tumor growth and bone resorption. Three days of 
treatment with 1 nM of Aplidin or Btz as single agents did 
not significantly decrease IgG2b levels in CM from bones 
bearing MM cells, whereas treatment with Dex alone 
modestly decreased MM growth. In contrast, combined 
administration of Aplidin and Dex or Aplidin and Btz 
significantly decreased tumor burden, demonstrating 
that Dex and Btz exhibit additive effects with Aplidin, 
enhancing its anti-MM properties (Figure 6C). After 12 
days, 1nM Aplidin alone decreased tumor growth by 40%, 
and no additional significant decreases in MM cell burden 
occurred when combined with Dex or Btz (Supplementary 
Figure 2B).
CM from bones bearing MM and treated under 
vehicle conditions cells had increased CTX levels 
compared to control bones not bearing MM cells (Figure 
6C). Treatment with Aplidin, Dex, or Btz alone did not 
alter the increased CTX levels in CM MM myeloma-
bearing bones after 3 days. In contrast, treatment with 
combinations of Aplidin and Dex decreased CTX 
levels in CM from MM-bearing bones (Figure 6C). Co-
administration of Aplidin and Btz also decreased CTX 
levels, however these results did not reach statistical 
significance (Figure 6C). After 12 days, Aplidin alone 
reduced CTX in bones bearing MM by 60%. Moreover, 
Aplidin in combination with Dex and Btz, completely 
prevented the increased bone resorption induced by MM 
cells, with CTX levels no different from those observed in 
CM from control bones (Supplementary Figure 2B). 
DISCUSSION
Bone destruction is the hallmark of MM, with 
approximately 70% MM patients presenting with 
osteolytic lesions at the time of diagnosis. Despite the 
abundance of new drugs recently approved for the 
treatment of MM, the disease remains incurable and the 
skeletal consequences persist even after achievement of 
long-term tumor remission. Further, many anti-tumor 
treatments have adverse effects on bone (i.e. Dex, 
alkylators, long-term bisphosphonate administration), 
resulting in more rapid and severe bone destruction [5]. 
Thus, new more effective therapeutic approaches that 
improve anti-tumor responses and maintain bone health 
in patients with MM are needed. The results of this 
study demonstrate that Aplidin decreases MM growth 
and enhances the efficacy of other chemotherapy drugs 
(Btz and Dex) on MM cells (Figure 7). In addition, we 
found that Aplidin targets pre-osteoclasts and mature 
osteoclasts and potently inhibits their differentiation and 
bone resorptive activity. Further, Aplidin acts additively 
with Btz to inhibit MM cell-induced bone resorption in 
an ex vivo model of MM bone disease. The potent anti-
resorptive activity of Aplidin found in our studies, together 
with its potent activity against MM cells, strongly suggest 
Figure 5: Aplidin decreases the number and activity of mature osteoclasts. (A) Number of TRAP+ mature osteoclasts and 
protein expression of Cathepsin K after treatment with Aplidin for 3 days in the presence/absence of RANKL. (B) Resorption pits formed 
on bovine bone slices by mature osteoclasts treated with Aplidin for 3 days. Representative images out of 4 independent replicas are shown 
per each condition. Representative experiments out of two are shown (n = 4 per condition). Bars represent means ± SD. *p < 0.05 Aplidin 
alone vs vehicle.
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that treatment with Aplidin could simultaneously block 
MM growth and bone destruction in MM patients.
Our studies show for the first time that Aplidin 
exhibits a potent anti-resorptive activity through direct 
actions on osteoclast precursors and mature osteoclasts. 
These cells exhibited a very high sensitivity to Aplidin 
compared to MM cells and other bone cells (picomolar 
versus nanomolar doses). Aplidin decreased Cathepsin K 
protein expression in mature osteoclasts, and prevented 
osteoclast differentiation by blocking the induction of 
osteoclast differentiation markers (NFATc1, TRAP, MMP-
9) and inhibiting the rapid ERK phosphorylation induced 
by RANKL signaling, key molecular events required for 
proper osteoclast formation and function [17]. This latter 
observation is in line with previous findings showing that 
Aplidin decreases ERK1/2 and ERK 5 phosphorylation in 
MM cells [9]. However, unlike in MM cells, Aplidin did not 
stimulate or altered RANKL-induced p38 phosphorylation, 
suggesting that Aplidin differentially regulates MAPK 
signaling pathways in non-tumor vs tumor cells.
High dose of glucocorticoids (GCs) is a frequent 
component of anti-MM therapy due to its ability to 
Figure 6: Aplidin decreases tumor growth and inhibits bone resorption in an ex vivo bone organ model of multiple 
myeloma. The levels of the tumor growth marker IgG2b and the bone resorption marker CTX were evaluated in conditioned media 
collected from control bones and bones bearing 5TGM1 MM cells. (A) Bright field pictures show the piece of calvarial bone and GFP 
fluorescent images show 5TGM1-GFP MM cells within the bone. Bones bearing MM cells were cultured with/without Aplidin alone (B) 
or combined with Dex and Btz (C). IgG2b and CTX levels were determined after 3 days. Percent change was calculated over bones bearing 
MM cells and cultured under vehicle conditions. Combined results of two independent ex vivo studies are shown. 4-6 independent calvarial 
bones were used per condition/experiment. Bars represent means ± SD. *p < 0.05 vs MM-veh; lines indicate p values < 0.05 comparing 
MM-Dex/Btz alone vs MM-Dex/Btz + Aplidin.
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induce apoptosis of MM cells and capacity to enhance 
the efficacy of other chemotherapy drugs [18–20]. 
However, GCs cause rapid bone loss by increasing bone 
resorption, inducing osteoblast and osteocyte apoptosis, 
and reducing bone formation [21–23]. In contrast, Btz, 
also used as a frontline agent for the treatment of MM, 
can induce transient decreases in bone resorption and 
increase osteoblast number and bone formation markers 
[24]. Our in vitro results show that Aplidin counteracted 
the increase in osteoclasts differentiation induced by 
Dex, whereas in combination with Btz, it induced a more 
potent suppression of osteoclast differentiation and bone 
resorption than each agent alone. Together, these results 
show the potential of combining Aplidin with GCs or Btz 
for the treatment of MM, as these combination therapies 
could prevent tumor growth whilst reducing the bone loss 
induced by MM cells and mitigate the adverse effects of 
GCs on the skeleton.
Our proliferation and cell death studies in human 
and murine MM cells lines demonstrate that Aplidin 
exhibits anti-proliferative and pro-apoptotic activities 
in MM cells. In addition, combination of Aplidin with 
other anti-MM drugs induces better responses than each 
treatment alone, demonstrating that Aplidin enhances 
the anti-MM effects of Dex. This is consistent with 
previous findings showing that co-administration of 
Aplidin and Dex results in additive anti-MM effects [9], 
and with more recent results of phase III clinical trials 
demonstrating that patients with relapsed/refractory MM 
treated with combined combination of Aplidin and Dex 
had a significantly 35% lower risk of disease progression 
or death when compared to Dex alone (6). Further, Aplidin 
decreased the viability of JJN3 cells and enhanced their 
response to Btz. JJN3 cells have mutated p53, which can 
contribute to resistance to Btz and poor outcomes in MM 
patients [25]. Our findings are in line with a previous 
publication showing additive effects of Aplidin against 
MM cells when combined with Btz [9]. However, it 
remains unclear whether co-administration of Aplidin 
could overcome resistance to proteasome inhibitors and 
Dex. Together, these data suggest that Aplidin has a 
unique mechanism of action that does not interfere with 
pathways targeted by other anti-tumor drugs. In addition, 
our findings suggest that Aplidin could be effective against 
MM cells resistant to frequent components of anti-MM 
therapy and may help to overcome the drug resistance that 
patients develop over the course of treatment. 
Treatment with Aplidin also induced cell death in 
osteocytes (via apoptosis), and osteoblasts, and enhanced 
the cell death induced by Dex in these cell types. Our 
results also suggest that co-administration of Aplidin and 
Dex leads to further decreases in tumor growth than each 
agent alone. However, this combination could further 
suppress osteoblast number in bones bearing MM. In 
contrast, we found that Btz alone did not affect osteoblast/
osteocyte viability, but it partially prevented the increased 
osteocyte/osteoblast cell death induced by Aplidin. This 
is consistent with a previous report showing that Btz 
prevents osteocyte cell death induced by Dex and MM 
cells in vitro, and that patients treated with Btz exhibit 
higher numbers of viable osteocytes compared with those 
not treated with Btz [26]. Mechanistic studies revealed 
that these protective effects of Btz are due to inhibition 
of osteocyte apoptosis and autophagic cell death [26]. 
Figure 7: Working model. Aplidin inhibits MM cell viability, decreases osteoblast/osteocyte viability, and inhibits osteoclast 
differentiation and function. Co-administration of Aplidin enhances the anti-MM activity of Btz and Dex (1). Further, when combined with 
Aplidin, Btz increases the anti-resorptive properties of Aplidin (2), and partially prevents the decreases in osteoblast/osteocyte viability 
and osteoblast function induced by Aplidin (3). In contrast, Dex increases bone resorption (4) and in combination with Aplidin further 
decreases osteoblasts/osteocyte viability (5). Thus, administration of Aplidin as a single agent has the potential to simultaneously inhibit 
tumor growth and prevent bone destruction by inhibiting bone resorption. Moreover, in combination with Btz, it could result in superior 
anti-MM and anti-resorptive activities than each agent alone, as well as ameliorate the deleterious effects of Aplidin on osteoblasts/
osteocytes. Finally, although co-administration of Dex and Aplidin could also result in enhanced anti-MM effects, Dex may antagonize the 
anti-resorptive activity of Aplidin and further increase osteoblasts/osteocyte cell death.
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Similar to a previous report showing that Btz induced 
transient increases in osteoblast and circulating markers 
of bone formation [24], we found that Btz mitigated the 
reduction in osteoblast mineralization induced by Aplidin. 
Thus, combined administration of Aplidin and Btz could 
result in superior anti-MM activity, stronger suppression 
of bone resorption, and ameliorate the potential negative 
effects of Aplidin on bone formation. Future studies are 
warranted to examine the effects of Aplidin alone and in 
combination with current anti-MM drugs in in vivo models 
of MM-induced bone disease.
Our bone organ culture that reproduces the 
3D-organization and the cellular diversity of the MM/
bone marrow niche allowed us to examine the effect of 
Aplidin simultaneously on MM and bone cells, thereby 
providing a model closer to an in vivo scenario. Using 
this innovative approach, we demonstrated that Aplidin 
decreased MM cell growth and osteoclast-mediated bone 
resorption in bones bearing MM cells, and that suboptimal 
doses of Aplidin in combination with Dex and Btz have 
additive effects against MM cells and decrease resorption 
to a larger extent that each treatment alone. These ex 
vivo results demonstrate that Aplidin can inhibit bone 
resorption in the MM/bone marrow microenvironment 
and provide additional support for combining Aplidin 
with other anti-MM drugs for the treatment of MM. 
However, further studies are needed to evaluate if Aplidin 
also inhibits bone resorption and has combinatorial effects 
when co-administered with other anti-MM drugs in murine 
models of MM disease and MM patients. 
In summary, our study increases the potential of 
Aplidin as a therapy for MM by demonstrating its effects 
on MM-induced bone disease. We show that Aplidin is a 
potent anti-resorptive agent that inhibits bone resorption 
by acting directly on osteoclast precursors and mature 
osteoclasts. Further, the anti-tumor and anti-resorptive 
properties of Aplidin are preserved and/or enhanced when 
combined with frequent components of anti-MM therapy. 
Together, these findings provide the framework for 
additional preclinical and clinical studies of this agent for 
the treatment of MM and its associated skeletal disease.
MATERIALS AND METHODS 
Reagents
RPMI-1640, α-MEM, glutamine, penicillin, and 
streptomycin were purchased from Invitrogen Life 
Technologies (Grand Island, NY, USA). Aplidin was 
provided by PharmaMar S.A. (Madrid, Spain). Bortezomib 
(Btz) was purchased from Selleckchem.com (Houston, 
TX, USA), and Dexamethasone (Dex) from Sigma-
Aldrich (St Louis, MO, USA). MTT from Invitrogen. 
Murine anti-p-ERK antibody (Cat. # 9101), anti-ERK 
antibody (Cat. #9102), anti-p-P38 antibody (Cat.# 9211) 
and anti-P38 antibody (Cat.#9212) and anti-GAPDH 
antibody (Cat.#2118) were purchased from Cell Signaling 
Technology (Danvers, MA, USA); β-ACTIN antibody 
(ab49900) from Abcam (Cambridge, MA, USA); anti-
NFACT1 antibody (Cat.# sc-7294); anti-MMP9 (Cat.# sc-
393859); anti-TRAP (Cat.# sc-28204); and anti-Cathepsin 
K antibody (Cat.# sc-6507) from Santa Cruz Biotechnology 
Inc. (Dallas, TX, USA); and anti-DC-STAMP antibody 
(Cat.# MABF39-1) from Millipore (Temecula, CA, USA). 
Human RANKL and M-CSF were purchased from R&D 
systems (Minneapolis, MN, USA); and bone slices for 
osteoclast resorption from Immunodiagnostic Systems Inc. 
(Gaithersburg, MD, USA).
Cells and culture conditions
Human JJN3 and murine 5TGM1 MM cell lines, 
commonly used in our laboratory to model MM growth 
and bone disease in rodents [14, 30], were provided by 
N. Giuliani (University of Parma, Italy) and B. Oyajobi 
(University of Texas at San Antonio, TX, USA), 
respectively. Murine MLO-A5 osteocyte-like cells were 
provided by L. Bonewald (Indiana University, IN, USA) 
[27, 28]. OB-6 osteoblast-like cells were obtained from 
R. Jilka (University of Arkansas for Medical Sciences) 
[29]. MC3T3-subclone MC4 pre-osteoblastic cells were 
obtained from G.D. Roodman (Indiana University). 
5TGM1 and JJN3 MM cells, MC4 pre-osteoblastic cells, 
OB-6 osteoblastic cells, and MLO-A5 osteocyte-like cells 
were cultured as previously published [13, 14, 30]. All 
cell lines were tested for morphology, gene expression 
profile, and tumorigenic capacity (MM cells) according to 
previous publications and proved to be mycoplasma free. 
Cell viability
5TGM1 and JJN3 MM cells (3 × 105 cells/mL), and 
OB-6 osteoblastic cells and MLO-A5 osteocyte-like cells 
(1.5 × 104 cell/cm2) were treated for 24 h and 48 hours 
with Aplidin (1–180 nM) in the presence or absence of 
Btz (3 nM) or Dex (10−5 M). Btz/Dex doses were selected 
based on previous studies showing that treatment with 
these concentrations decreases JJN3 and 5TGM1 cell 
viability by ~50% [30], thus allowing us the detection of 
combinatorial effects when co-administered with Aplidin. 
JJN3 MM cells and MLO-A5 osteocyte-like cells were 
pre-incubated with DEVD (100 nM) for 4 h and then 
treated with Aplidin 10nM for 48h. DEVD was refreshed 
every 24 h. DMSO and ethanol were used as controls for 
these experiments. After treatment, 5TGM1 and JJN3 MM 
cells, OB-6 osteoblastic cells, and MLO-A5 osteocyte-
like cells were pelleted and resuspended in media. Cell 
death was quantified by Trypan blue uptake as described 
[14, 30], and cell viability was examined by MTT assays 
following protocols established by the manufacturer. 
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Osteoblast differentiation
MC-4 and OB-6 osteoblastic cells (5000 cells/cm2) 
were cultured with osteogenic media (0.2 mM ascorbic 
acid, 10 mM β-glycerophosphate) as previously described 
[13, 14], and treated with Aplidin (1 and 10 nM), alone 
or in combination with Btz (3nM) every 3 days or once 
per week. Media were replaced every 2–3 days, and 
mineralization was determined by Alizarin Red staining 
and quantified as described before [13].
CFU-GM colony formation
Murine non-adherent bone marrow cells (1 × 
105cells/culture) were cultured in α-MEM (Gibco, Grand 
Island, NY) containing 1.2% methylcellulose, 30% FBS, 
1% deionized bovine serum albumin (BSA) (Sigma-
Aldrich), and 100 ng/mL recombinant human GM-CSF 
(Immunex Corp., Seattle, WA, USA). The cells were 
plated in a volume of 1.0 mL in 35-mm culture dishes 
(Corning, New York, NY), as reported previously [31], 
and treated with or without Aplidin (5 pM and 50 pM). 
The number of colonies that formed were scored after 7 
days of culture using an inverted microscope.
Osteoclast formation from murine bone marrow
Bone marrow cells were flushed out from long 
bones of C57BL/6 mice and cultured in α-MEM 
containing 10% FBS overnight. Non-adherent cells were 
harvested and enriched for CD11b+ mononuclear cells 
as described previously [32]. To determine the effects of 
Aplidin on the growth of osteoclast precursors, CD11b+ 
cells were cultured in α-MEM containing 10% FBS 
plus 10 ng/mL of M-CSF for 3 days in the presence or 
absence of Aplidin (0.01–10 pM). To assess the effects of 
Aplidin on osteoclast differentiation, CD11b+ cells were 
cultured in α-MEM containing 10% FBS plus 10 ng/mL 
of M-CSF for 3 days and then treated with RANKL (50 
ng/mL) for 4 days in the presence/absence of Aplidin 
(0.01–10pM), Btz (3 nM), and Dex (10−7  M). RANKL and 
other treatments were replenished every two days. Cells 
were stained for TRAP using a leukocyte acid phosphatase 
kit (Sigma-Aldrich), and TRAP-positive mononuclear 
cells and multinuclear cells (≥3 nuclei/cell) were scored 
microscopically after M-CSF for 3 days or after RANKL 
for 4 days respectively, as described previously [32]. 
Isolation of mature osteoclasts from mouse bone 
marrow cultures and bone resorption assays
Bone marrow cells were flushed out from long bones 
of C57BL/6 mice and cultured in a 10-cm dish (2.5 × 107 
cells/dish) with M-CSF (10 ng/ml) for 3 days and RANKL 
(50 ng/ml) for 4 days as previously described [32]. Then, 
cells were incubated with trypsin EDTA (Corning) for 
3 minutes to remove non-osteoclastic cells and enrich 
the concentration of mature osteoclasts in the cultures. 
Mature osteoclasts (1 × 104/well in 96-well plates) were 
treated with or without Aplidin (0.1–10 pM) for 3 days 
in the presence/absence of RANKL (50 ng/ml). For 
bone resorption assays, 5 × 104 mature osteoclasts were 
transferred to bovine slices and cultured with RANKL 
(50 ng/mL) and treated with Aplidin (0.1 and 10 pM) in 
the presence or absence of Btz (3 nM) and Dex (10−7 M) 
for 3 or 7 days. RANKL (50 ng/mL) was added every two 
days to the resorption assays.
Western blot analysis
Protein lysates were prepared from osteoclast 
precursors undergoing differentiation and from mature 
osteoclasts as previously described [15]. Cell lysates (25 
µg) were boiled in the presence of sodium dodecyl sulfate 
(SDS) sample buffer (0.5 M Tris–HCl, pH 6.8, 10% wt/vol 
SDS, 10% glycerol, 0.05% wt/vol bromophenol blue) for 
5 minutes and subjected to electrophoresis on 4% to 20% 
SDS -PAGE (Bio-Rad Laboratories, Hercules, CA, USA). 
Proteins were transferred to nitrocellulose membranes 
using a semidry blotter (Bio-Rad) and incubated in 
blocking solution (5% nonfat dry milk in TBS containing 
0.1% Tween-20) for 1 hour to reduce nonspeciﬁc binding. 
Membranes were washed extensively and immunoblots 
were performed using anti-p-ERK (1:1000), anti-ERK 
(1:1000), anti-p-P38 (1:1000), anti-P38 (1:1000), anti-
NFACT1 (1:1000), anti-CATHEPSIN K (1:1000), 
anti-DC-STAMP (1:500), anti-GAPDH (1:2000), anti-
MMP9 (1:1000), anti-TRAP (1:200), and anti-β-ACTIN 
(1:4000) antibodies followed by rabbit anti-goat or 
goat anti-mouse antibodies respectively, conjugated to 
horseradish peroxidase (1:2000) in 5% milk, Santa Cruz 
Biotechnology). Western blots were developed using an 
enhanced chemiluminescence detection assay following 
the manufacturer’s directions (Bio-Rad). 
Ex vivo bone organ cultures
Bone organ cultures were established as previously 
described [14]. Briefly, calvarial bones from 9–15 day-
old mouse C57BL/6 pups were cut into 3.5 mm disks 
with a biopsy punch and placed into 24-well plates. 5 
× 104 5TGM1 MM cells were added in 0.5 ml of RPMI 
medium supplemented with 10% fetal calf serum and 
antibiotics. Bones bearing MM cells were washed with 
PBS, transferred to a new plate, and treated with Aplidin 
(1 nM or 10 nM) in the presence or absence of Btz (3 
nM) and Dex (10−5 M). Conditioned media was collected 
3 and 12 days after treatments for assessment of tumor 
growth by IgG2b levels and bone resorption markers by 
C-terminal telopeptides of type I collagen (CTX). Half of 
the media was replaced every 3 days until day 7, when 
100% of media was replaced with fresh culture media. 
Murine IgG2b concentrations in conditioned media 
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were determined using commercially available enzyme-
linked immunosorbent assays (ELISA) kits, according 
to manufacturer instructions (Bethyl Laboratories, Inc., 
Montgomery, TX, USA). CTX levels in conditioned media 
were quantified by ELISA (Immunodiagnostics Systems) 
as previously published [33]. 
Statistics
Data were analyzed using SigmaPlot 12.0 (Systat 
Software, Inc., San Jose, CA, USA). All values are 
reported as means ± SD. Differences between treatment 
groups were evaluated using One-way ANOVA. p ≤ 0.05 
was considered statistically significant.
Study approval
Studies using animal samples (calvarial bones) were 
approved by the Indiana University School of Medicine’s 
IACUC.
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